AAO Journal Archive
- Classification of Vitreous Seeds in Retinoblastoma
- Topical 5-Fluorouracil 1% as Primary Treatment for Ocular Surface Squamous Neoplasia
- Individualized Stabilization Criteria–Driven Ranibizumab versus Laser in Branch Retinal Vein Occlusion
- Correlation of Histologic Features with In Vivo Imaging of Reticular Pseudodrusen
- Pseudodrusen and Incidence of Late Age-Related Macular Degeneration in Fellow Eyes in the Comparison of Age-Related Macular Degeneration Treatments Trials
- Pharmacotherapies for Retinal Detachment
- Can Automated Imaging for Optic Disc and Retinal Nerve Fiber Layer Analysis Aid Glaucoma Detection?
- Suture Colonization Rate in Adjustable Strabismus Surgery
- Genetic and Dietary Factors Influencing the Progression of Nuclear Cataract
- Diagnostic Accuracy of Optical Coherence Tomography and Scanning Laser Tomography for Identifying Glaucoma in Myopic Eyes
- Details
To compare the efficacy of whole genome sequencing (WGS) with targeted next-generation sequencing (NGS) in the diagnosis of inherited retinal disease (IRD).
- Details
Wolfram syndrome, or diabetes insipidus, diabetes mellitus, optic atrophy [OA], and deafness (DIDMOAD), is a neurodegenerative disorder with heterogeneous clinical manifestations caused by homozygous or compound heterozygous recessive mutations in the WFS1 gene (OMIM 606201).1 More recently, the phenotypic spectrum has expanded to include patients with dominant inheritance and limited clinical features, in particular OA in association with diabetes mellitus and/or sensorineural deafness.1 WFS1 encodes for an endoplasmic reticulum transmembrane protein, Wolframin, which is highly expressed in retinal tissues, including retinal ganglion cells, the photoreceptor inner segments, and the inner nuclear layer (INL) of the human eye, and mouse Müller cells.
Read more: Lamination of the Outer Plexiform Layer in Optic Atrophy Caused by Dominant Mutations
- Details
To investigate the association between oral contraceptive (OC) use and glaucoma prevalence in the United States.
- Details
To investigate the comparative efficacy of bevacizumab (Avastin) and ranibizumab (Lucentis; both Genentech, Inc, South San Francisco, CA) for diabetic macular edema (DME) using a crossover study design.
- Details
To assess the prevalence of subretinal drusenoid deposits (SDD) in older adults with healthy maculas and early and intermediate age-related macular degeneration (AMD) using multimodal imaging.